Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
Primary Purpose
Insomnia
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Sound Treatment
Sponsored by
About this trial
This is an interventional treatment trial for Insomnia
Eligibility Criteria
Inclusion Criteria: 18 years of age and older Meets DSM 5 criteria for insomnia disorder Insomnia Severity Index (ISI) of 15 - 28 Exclusion Criteria: Use of sleep medications, sedating or alerting medications or antidepressants in the last 3 months Diagnosis of any autoimmune disorder or any medical or sleep disorder that could affect sleep Pregnancy
Sites / Locations
- San Francisco Otolaryngology Medical GroupRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Intervention
Arm Description
Treatment using a customized sound audio track delivered via standard commercially available bone conduction headsets
Outcomes
Primary Outcome Measures
Change in Insomnia Severity Index (ISI)
Reduction in Insomnia Severity
Secondary Outcome Measures
Change in Pittsburgh Sleep Quality Index (PSQI)
Reduction in Sleep Quality
Full Information
NCT ID
NCT06021795
First Posted
August 27, 2023
Last Updated
September 20, 2023
Sponsor
Third Wave Therapeutics
1. Study Identification
Unique Protocol Identification Number
NCT06021795
Brief Title
Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
Official Title
Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2023 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Third Wave Therapeutics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Assess the effect of a customized audio track delivered via standard commercially-available bone conduction headsets on the quality of sleep
Detailed Description
A single-center study in 25 subjects suffering from moderate to severe insomnia and assess the effectiveness of the intervention. Intervention consists of treatment using a customized audio track delivered via standard commercially-available bone conduction headsets daily for four (4) weeks. Effectiveness is defined by a statistically significant improvement in Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) at baseline versus the end of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Treatment using a customized sound audio track delivered via standard commercially available bone conduction headsets
Intervention Type
Device
Intervention Name(s)
Sound Treatment
Intervention Description
Customized sound audio track delivered via standard commercially available bone conduction headset
Primary Outcome Measure Information:
Title
Change in Insomnia Severity Index (ISI)
Description
Reduction in Insomnia Severity
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Change in Pittsburgh Sleep Quality Index (PSQI)
Description
Reduction in Sleep Quality
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age and older
Meets DSM 5 criteria for insomnia disorder
Insomnia Severity Index (ISI) of 15 - 28
Exclusion Criteria:
Use of sleep medications, sedating or alerting medications or antidepressants in the last 3 months
Diagnosis of any autoimmune disorder or any medical or sleep disorder that could affect sleep
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paramesh Gopi, PhD
Phone
408-316-3631
Email
pgopi@soundhealth.life
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Elan Hekier, MD
Organizational Affiliation
San Francisco Otolaryngology Medical Group
Official's Role
Principal Investigator
Facility Information:
Facility Name
San Francisco Otolaryngology Medical Group
City
San Francisco
State/Province
California
ZIP/Postal Code
94108
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elan Hekier
Phone
415-362-5443
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia
We'll reach out to this number within 24 hrs